Unlocking the Potential: ORIC-114’s Initial Phase 1 Dose Escalation Data in Patients with EGFR and HER2 Exon 20 Mutations
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Promising Results CNS Activity and Systemic Responses ORIC Pharmaceuticals recently presented exciting preliminary data from the Phase 1 clinical trial of ORIC-114, a promising new treatment for patients with EGFR and HER2 exon 20 mutations. The data…